BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38282550)

  • 1. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
    Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
    Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.
    Cui J; Chen X; Zhai Q; Chen N; Li X; Zhang Y; Wang H; Bian X; Gao N; Chen D; Chen Z; Zhang S; Chen Y
    Diagn Pathol; 2023 Feb; 18(1):19. PubMed ID: 36765365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
    Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
    Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
    Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ
    Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
    Dong S; Zakaria H; Hsiehchen D
    Oncologist; 2022 Mar; 27(3):159-162. PubMed ID: 35274726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
    van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
    Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
    Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
    Li Y; Bian Y; Wang K; Wan XP
    BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
    Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
    PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
    Rocque MJ; Leipart V; Kumar Singh A; Mur P; Olsen MF; Engebretsen LF; Martin-Ramos E; Aligué R; Sætrom P; Valle L; Drabløs F; Otterlei M; Sjursen W
    Mol Genet Genomics; 2023 May; 298(3):555-566. PubMed ID: 36856825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
    Bellone S; Centritto F; Black J; Schwab C; English D; Cocco E; Lopez S; Bonazzoli E; Predolini F; Ferrari F; Silasi DA; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2015 Jul; 138(1):11-7. PubMed ID: 25931171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.